Gelonghui, April 8 | Hongyuan Pharmaceutical (301246.SZ) said on the investor interactive platform that the lithium battery materials industry is currently experiencing phased overcapacity, but the lithium battery industry will maintain a relatively rapid growth rate in the long run. In the future, the company will continue to enhance the competitiveness of the company's lithium hexafluorophosphate business through technological iterative upgrading and expansion upstream of the industrial chain. At the same time, it will lay out products such as additives and functional lithium salts, form industrial collaboration with the lithium hexafluorophosphate business, and continue to enhance the business scale and market competitiveness of the company's lithium battery sector. The company fulfills its information disclosure obligations in strict accordance with regulatory regulations and laws and regulations, and the company will promptly disclose the company's operating performance in the form of annual reports, semi-annual reports, quarterly reports, and performance forecasts.